SCHEMBL24923652

SCHEMBL24923652

Cc1nn(C2CCCC2)cc1C(C)C

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSP90AA1 P07900 2/20 0.37
HSP90AB1 P08238 2/20 0.37
ACHE P22303 3/20 0.36
AADAT Q8N5Z0 1/20 0.34
DRD2 P14416 1/20 0.34
DRD4 P21917 1/20 0.34
DRD3 P35462 1/20 0.34
PSMB8 P28062 3/20 0.33
PSMB9 P28065 3/20 0.33
KDM4E B2RXH2 1/20 0.33
ALDH1A1 P00352 1/20 0.33
HSD17B10 Q99714 1/20 0.33
KDM5A P29375 1/20 0.32
LRRK2 Q5S007 1/20 0.32
IDO1 P14902 1/20 0.32
HPGD P15428 1/20 0.32
CCNT1 O60563 1/20 0.32
CDK9 P50750 1/20 0.32
NR3C1 P04150 2/20 0.31
KDM5B Q9UGL1 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21238766 0.93 DRD2 (0.35) HSP90AA1HSP90AB1DRD2DRD4DRD3
SCHEMBL22474446 0.86 LRRK2 (0.43) DRD2DRD4DRD3LRRK2
SCHEMBL25556777 0.85 ALOX15 (0.40) DRD2DRD4DRD3KDM5ALRRK2
SCHEMBL25556775 0.85 CHRNB2 (0.44) ALDH1A1KDM5A
SCHEMBL24923932 0.83 DRD2 (0.34) ACHEDRD2DRD4DRD3PSMB8
SCHEMBL26499974 0.82 ACHE (0.33) ACHEDRD2DRD4DRD3PSMB8
SCHEMBL25556783 0.82 KDM5A (0.32) KDM5A
SCHEMBL24837078 0.81 ALDH1A2 (0.33) ALDH1A1KDM5ALRRK2
SCHEMBL25556594 0.81 HTR2A (0.33) KDM5A
SCHEMBL24152761 0.77 ALDH1A1 (0.39) ACHEAADATDRD2DRD4DRD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11787780-B2 Quaternary indazole glucocorticoid receptor antagonists CORCEPT THERAPEUTICS INCORPORATED (US) 2023-10-17 US disclosed
US-11787780-B2 Quaternary indazole glucocorticoid receptor antagonists CORCEPT THERAPEUTICS INCORPORATED (US) 2023-10-17 US disclosed
US-20230032612-A1 QUATERNARY INDAZOLE GLUCOCORTICOID RECEPTOR ANTAGONISTS CORCEPT THERAPEUTICS INCORPORATED 2023-02-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11787780-B2 Quaternary indazole glucocorticoid receptor antagonists NR3C1, NR3C2, MC2R HSP90AA1 3422/4885HSP90AB1 2835/4885ACHE 4743/4885
US-20230032612-A1 QUATERNARY INDAZOLE GLUCOCORTICOID RECEPTOR ANTAGONISTS NR3C1, NR3C2, MC2R HSP90AA1 3422/4885HSP90AB1 2835/4885ACHE 4743/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.